Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2022-02-14 Capital/Financing Update
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the U.S. Securities and Exchange Commission. It is a preliminary prospectus for an initial public offering (IPO) of common stock by MAIA Biotechnology, Inc. The text includes detailed information about the company, its pipeline, risk factors, use of proceeds, capitalization, management, and underwriting. This type of filing is related to capital raising and securities registration rather than a financial report, earnings release, or management discussion. The Form S-1 is a registration statement used for IPOs and other securities offerings, which fits the category of Capital/Financing Update (CAP). The document is not an announcement of a report but the actual registration statement/prospectus text, and it is lengthy (15,000 characters), so it is not a mere report publication announcement or regulatory filing. Therefore, the best classification is Capital/Financing Update (CAP).
2022-02-14 English
Regulatory Filings 2022
Regulatory Filings
2022-01-11 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from MAIA Biotechnology, Inc. to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on their Draft Registration Statement on Form S-1. The letter addresses SEC comments on the company's registration statement, including disclosures about their lead product candidate, risk factors, use of proceeds, management's discussion and analysis, and other regulatory compliance matters. The presence of references to Form S-1, responses to SEC comment letters, and amendments to the registration statement clearly indicate this is a regulatory filing related to a securities offering, specifically an IPO registration statement process. This type of document is not an annual report, earnings release, or any other financial report but a regulatory filing responding to SEC review comments on a registration statement. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory correspondence.
2021-12-22 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the U.S. Securities and Exchange Commission. It is a preliminary prospectus for an initial public offering (IPO) of common stock by MAIA Biotechnology, Inc. The text includes detailed information about the company, its business, product pipeline, risk factors, management, and underwriting details. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or a regulatory filing of a different nature. The Form S-1 is a registration statement used for securities offerings and is classified under capital/financing updates as it relates to fundraising and capital market activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement and prospectus, not just an announcement or summary.
2021-12-22 English
Regulatory Filings 2021
Regulatory Filings
2021-11-16 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by MAIA Biotechnology, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the company, its business, lead product candidate, risk factors, use of proceeds, capitalization, management, executive compensation, and other disclosures typical of an IPO registration statement. This type of filing is a registration statement under the Securities Act of 1933, not an annual report, earnings release, or other financial report. It is not a report publication announcement or a regulatory filing in the fallback sense, but the actual registration statement document. The Form S-1 is a specific SEC filing category for IPO registration statements and is not explicitly listed in the provided categories. However, the closest and most appropriate category from the given list is "Regulatory Filings (RNS)" because it covers general regulatory announcements and compliance documents that do not fit other categories, including registration statements for securities offerings. Therefore, the document should be classified as Regulatory Filings (RNS) with high confidence.
2021-10-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.